MAKING TREATMENT
DECISIONS IN MS
WITH THE FUTURE IN MIND

Shared Treatment Decision-Making Throughout the MS Journey

Every MS patient has different wants, needs and desires, and MS affects each of them differently and is continually evolving. In addition, the treatment landscape of MS looks very different now than it did 10 years ago. All this means that treatment can and should be tailored to the individual patient throughout their MS journey, addressing immediate clinical and personal needs while considering later options. In practice, this involves thinking about a number of factors, related to the patient, their disease and the therapy, to make the best decision for the patient at any point in time.

TAILORING TREATMENT TO THE INDIVIDUAL PATIENT IS VITAL WHEN MAKING TREATMENT DECISIONS1,2

  • Patient-related factors
    Unique patient profile, risk tolerance, workability, family planning1,3

  • Disease-related factors
    Clinical and radiological, hidden symptoms, prognostic factors1,3-5

  • Treatment-related factors
    Impact on the immune system, MoA, benefit-risk, real-world experience1

Find out what this could look like with our MS patient avatar.

Biogen-60433.
Date of preparation: August 2020.

References:
1. Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017;264(12):2351-2374.
2. Lugaresi A, di Ioia M, Travaglini D, et al. Risk-benet considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat. 2013;9:893-914.
3. Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123-1136.
4. Roman C, Menning K. Treatment and disease management of multiple sclerosis patients: A review for nurse practitioners. J Am Assoc Nurse Pract. 2017;29(10):629-638.
5. Penner IK. Evaluation of cognition and fatigue in multiple sclerosis: daily practice and future directions. Review Acta Neurol Scand. 2016;134(Suppl.200):19-23.